Efficacy and safety of tolvaptan for better management of patients undergoing liver resection, prospective study

Efficacy and safety of tolvaptan for better management of patients undergoing liver resection, prospective study - Efficacy and safety of tolvaptan for liver resection, prospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041684

Enrollment

Registered

2021-01-01

Start date

2020-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

Tolvaptan use after liver resection for 1 week, as diuretics for postoperative edema from cirrhosis.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients preoperatively diagnosed with liver cirrhosis, who is scheduled to undergo liver resection for liver cancer.

Exclusion criteria

Exclusion criteria: The patients who rejected participation agreement

Design outcomes

Primary

Measure	Time frame
trend of body weight after surgery	—

Countries

Japan

Contacts

Public ContactYuta kobayashi

Toranomon hospital Hepato-biliary pancreas surgery division,Department of Gastroenterological Surgery

yuutakobayashi-ncd@umin.ac.jp0335881111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026